These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

350 related items for PubMed ID: 17869975

  • 1. Invasive candidiasis treated in the intensive care unit: observations from a randomized clinical trial.
    DiNubile MJ, Lupinacci RJ, Strohmaier KM, Sable CA, Kartsonis NA.
    J Crit Care; 2007 Sep; 22(3):237-44. PubMed ID: 17869975
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B.
    Dupont BF, Lortholary O, Ostrosky-Zeichner L, Stucker F, Yeldandi V.
    Crit Care; 2009 Sep; 13(5):R159. PubMed ID: 19804626
    [Abstract] [Full Text] [Related]

  • 5. A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis.
    Betts RF, Nucci M, Talwar D, Gareca M, Queiroz-Telles F, Bedimo RJ, Herbrecht R, Ruiz-Palacios G, Young JA, Baddley JW, Strohmaier KM, Tucker KA, Taylor AF, Kartsonis NA, Caspofungin High-Dose Study Group.
    Clin Infect Dis; 2009 Jun 15; 48(12):1676-84. PubMed ID: 19419331
    [Abstract] [Full Text] [Related]

  • 6. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006).
    Leroy O, Gangneux JP, Montravers P, Mira JP, Gouin F, Sollet JP, Carlet J, Reynes J, Rosenheim M, Regnier B, Lortholary O, AmarCand Study Group.
    Crit Care Med; 2009 May 15; 37(5):1612-8. PubMed ID: 19325476
    [Abstract] [Full Text] [Related]

  • 7. Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis.
    Keating G, Figgitt D.
    Drugs; 2003 May 15; 63(20):2235-63. PubMed ID: 14498760
    [Abstract] [Full Text] [Related]

  • 8. A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia.
    Maertens JA, Madero L, Reilly AF, Lehrnbecher T, Groll AH, Jafri HS, Green M, Nania JJ, Bourque MR, Wise BA, Strohmaier KM, Taylor AF, Kartsonis NA, Chow JW, Arndt CA, DePauw BE, Walsh TJ, Caspofungin Pediatric Study Group.
    Pediatr Infect Dis J; 2010 May 15; 29(5):415-20. PubMed ID: 20431381
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of micafungin for treatment of serious Candida infections in patients with or without malignant disease.
    Cornely OA, Marty FM, Stucker F, Pappas PG, Ullmann AJ.
    Mycoses; 2011 Nov 15; 54(6):e838-47. PubMed ID: 21668522
    [Abstract] [Full Text] [Related]

  • 10. Caspofungin for the treatment of less common forms of invasive candidiasis.
    Cornely OA, Lasso M, Betts R, Klimko N, Vazquez J, Dobb G, Velez J, Williams-Diaz A, Lipka J, Taylor A, Sable C, Kartsonis N.
    J Antimicrob Chemother; 2007 Aug 15; 60(2):363-9. PubMed ID: 17526917
    [Abstract] [Full Text] [Related]

  • 11. Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis.
    Colombo AL, Perfect J, DiNubile M, Bartizal K, Motyl M, Hicks P, Lupinacci R, Sable C, Kartsonis N.
    Eur J Clin Microbiol Infect Dis; 2003 Aug 15; 22(8):470-4. PubMed ID: 12884068
    [Abstract] [Full Text] [Related]

  • 12. Refractory neonatal candidemia and high-dose micafungin pharmacotherapy.
    Natarajan G, Lulic-Botica M, Aranda JV.
    J Perinatol; 2009 Nov 15; 29(11):738-43. PubMed ID: 19776753
    [Abstract] [Full Text] [Related]

  • 13. MSG-01: A randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting.
    Ostrosky-Zeichner L, Shoham S, Vazquez J, Reboli A, Betts R, Barron MA, Schuster M, Judson MA, Revankar SG, Caeiro JP, Mangino JE, Mushatt D, Bedimo R, Freifeld A, Nguyen MH, Kauffman CA, Dismukes WE, Westfall AO, Deerman JB, Wood C, Sobel JD, Pappas PG.
    Clin Infect Dis; 2014 May 15; 58(9):1219-26. PubMed ID: 24550378
    [Abstract] [Full Text] [Related]

  • 14. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.
    Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D, De Waele JJ, Vazquez JA, Dupont BF, Horn DL, Ostrosky-Zeichner L, Reboli AC, Suh B, Digumarti R, Wu C, Kovanda LL, Arnold LJ, Buell DN.
    Clin Infect Dis; 2007 Oct 01; 45(7):883-93. PubMed ID: 17806055
    [Abstract] [Full Text] [Related]

  • 15. Successful treatment with caspofungin of refractory Candida krusei candidemia in a very low birth weight preterm infant.
    Natale F, Castronovo A, Regoli D, De Curtis M, Manzoni P.
    Pediatr Infect Dis J; 2009 May 01; 28(5):452. PubMed ID: 19295457
    [No Abstract] [Full Text] [Related]

  • 16. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
    Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, Cornely OA, Bourque MR, Lupinacci RJ, Sable CA, dePauw BE.
    N Engl J Med; 2004 Sep 30; 351(14):1391-402. PubMed ID: 15459300
    [Abstract] [Full Text] [Related]

  • 17. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients.
    Zaoutis TE, Jafri HS, Huang LM, Locatelli F, Barzilai A, Ebell W, Steinbach WJ, Bradley J, Lieberman JM, Hsiao CC, Seibel N, Laws HJ, Gamba M, Petrecz M, Taylor AF, Strohmaier KM, Chow JW, Kartsonis NA, Ngai AL.
    Pediatrics; 2009 Mar 30; 123(3):877-84. PubMed ID: 19255017
    [Abstract] [Full Text] [Related]

  • 18. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial.
    Queiroz-Telles F, Berezin E, Leverger G, Freire A, van der Vyver A, Chotpitayasunondh T, Konja J, Diekmann-Berndt H, Koblinger S, Groll AH, Arrieta A, Micafungin Invasive Candidiasis Study Group.
    Pediatr Infect Dis J; 2008 Sep 30; 27(9):820-6. PubMed ID: 18679151
    [Abstract] [Full Text] [Related]

  • 19. A randomized, double-blind, prospective study of caspofungin vs. amphotericin B for the treatment of invasive candidiasis in newborn infants.
    Mohamed WA, Ismail M.
    J Trop Pediatr; 2012 Feb 30; 58(1):25-30. PubMed ID: 21355042
    [Abstract] [Full Text] [Related]

  • 20. [Micafungin in invasive candidiasis among oncohematological patients].
    Jarque I, Angel Sanz M.
    Rev Iberoam Micol; 2009 Mar 31; 26(1):75-7. PubMed ID: 19463282
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.